Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 46, 2014, Pages 17541-17551

  Inoue, Masafumi ^a   Takahashi, Yoshihisa ^b   Fujii, Takeshi ^a   Kitagawa, Masanobu ^c   Fukusato, Toshio ^b  

^a TORANOMON HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Hepatocellular adenoma; Hepatocellular carcinoma; Immunohistochemical staining; Liver fatty acid binding protein; catenin

Indexed keywords

BETA CATENIN; BINDING PROTEIN; CYTOKERATIN 19; CYTOKERATIN 7; FATTY ACID; GLUTAMATE AMMONIA LIGASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; SERUM AMYLOID A; FABP1 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; HNF1A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHOLANGIOCARCINOMA CELL LINE; CONTROLLED STUDY; DOWN REGULATION; EXON; FATTY LIVER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TISSUE MICROARRAY; TISSUE SECTION; TUMOR DIFFERENTIATION; TUMOR VOLUME; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL LINE, TUMOR; DOWN-REGULATION; FATTY ACID-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 84918544057     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i46.17541     Document Type: Article

References (25)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]
2. Kim do Y, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012; 1: 2-14 [PMID: 24159567 DOI: 10.1159/000339016]
3. Cabibbo G, Craxì A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2010; 14: 352-355 [PMID: 20496547]
4. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010; 24: 899-919, viii [PMID: 20937457 DOI: 10.1016/j.idc.2010.07.004]
5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]
6. Bioulac-Sage P, Balabaud C, Wanless I. Focal nodular hyperplasia and hepatocellular adenoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer, 2010: 198-204
7. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod Pathol 2008; 21: 491-497 [PMID: 18246041 DOI: 10.1038/modpathol.2008.8]
8. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G, Trillaud H, Zucman-Rossi J, Balabaud C, Saric J. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50: 481-489 [PMID: 19585623 DOI: 10.1002/hep.22995]
9. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, Bedossa P, Belghiti J. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137: 1698-1705 [PMID: 19664629 DOI: 10.1053/j.gastro.2009.07.061]
10. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43: 515-524 [PMID: 16496320 DOI: 10.1002/hep.21068]
11. Atshaves BP, Martin GG, Hostetler HA, McIntosh AL, Kier AB, Schroeder F. Liver fatty acid-binding protein and obesity. J Nutr Biochem 2010; 21: 1015-1032 [PMID: 20537520 DOI: 10.1016/j.jnutbio.2010.01.005]
12. Storch J, Thumser AE. Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 2010; 285: 32679-32683 [PMID: 20716527 DOI: 10.1074/jbc.R110.135210]
13. Smathers RL, Petersen DR. The human fatty acid-binding protein family: evolutionary divergences and functions. Hum Genomics 2011; 5: 170-191 [PMID: 21504868 DOI: 10.1186/147 9-7364-5-3-170]
14. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg 2010; 27: 39-45 [PMID: 20357450 DOI: 10.1159/000268406]
15. Theise ND, Curado MP, Franceschi S, Hytiroglou P, Kudo M, Park YN, Sakamoto M, Torbenson M, Wee A. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer, 2010: 205-216
16. Hepatocellular carcinoma. In: Ishak KG, Goodman ZD, Stocker JT. Tumors of the liver and intrahepatic bile ducts, 3rd series. Washington D.C.: Armed Forces Institute of Pathology, 2001: 199-230
17. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 5th ed. Tokyo: Kanehara, 2009
18. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405 [PMID: 15565571 DOI: 10.1002/hep.20486]
19. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Makuuchi M, Omata M. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419-425 [PMID: 15710994 DOI: 10.1136/gut.2003.035055]
20. Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiro M, Ichida T, Arii S, Yamaoka Y. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006; 41: 884-892 [PMID: 17048053 DOI: 10.1007/s00535-006-1878-y]
21. Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T. Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma. Hepatol Res 2013; 43: 959-969 [PMID: 23369163 DOI: 10.1111/hepr.12047]
22. Bluteau O, Jeannot E, Bioulac-Sage P, Marqués JM, Blanc JF, Bui H, Beaudoin JC, Franco D, Balabaud C, Laurent-Puig P, Zucman-Rossi J. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002; 32: 312-315 [PMID: 12355088 DOI: 10.1038/ng1001]
23. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011; 60: 85-89 [PMID: 21148580 DOI: 10.1136/gut.2010.222109]
24. Dal Bello B, Rosa L, Campanini N, Tinelli C, Torello Viera F, D'Ambrosio G, Rossi S, Silini EM. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res 2010; 16: 2157-2166 [PMID: 20233882 DOI: 10.1158/1078-0432.CCR-09-1978]
25. Suzuki T, Watanabe K, Ono T. Immunohistochemical demonstration of liver fatty acid-binding protein in human hepatocellular malignancies. J Pathol 1990; 161: 79-83 [PMID: 2164578]